Immuno insights

NavigAID for Immuno-Oncology


Oncimmune is able to detect autoantibodies for the prediction and monitoring of immune-related adverse events (irAEs), as well as therapeutic response for patients undergoing cancer immunotherapy, helping pharmaceutical and biotech companies develop safer, more effective immunotherapies.


Oncimmune’s research has shown that autoantibodies can be used as biomarkers for the onset of immune-related adverse events (irAEs), as well as predictors of overall survival for cancer patients undergoing immunotherapy. Together with its collaborative partners, Oncimmune is harnessing SeroTag to develop NavigAID tools for the profiling of autoantibodies that will enable the stratification of patients based on factors such as their disease profile, likely treatment response or incidence of irAEs.


The detection of autoantibody signatures in various cancers will enable the field to better predict immunotherapy response, and disease stratification will support the future development of safe and effective immunotherapies. As autoantibodies have already been shown to be powerful indicators of irAE incidence and therapeutic response, developing NavigAID panels for their detection will help the field of immuno-oncology to answer its most pressing questions.

If you would like to learn more about how these tools can help in the successful development of more effective, safer therapies…

 Contact us
full width image

NavigAID for Autoimmune Disease: Stratifying patients for improved therapeutic success


Autoimmune diseases are highly diverse, and the level of patient heterogeneity observed makes the development of effective treatments challenging. One solution is to stratify patients based on the specific characteristics of their individual autoimmune disease, including the detection of biomarkers that are central to the disease’s pathology—autoantibodies.


Developing tools to detect autoantibody signatures in patients suffering from autoimmune diseases will enable the immune-competence of a patient to be assessed, and their therapeutic responsiveness to be predicted.


The SeroTag biomarker identification platform has allowed Oncimmune to do this, and to develop an array of disease-specific NavigAID stratification panels to profile individual patients’ diseases. This enables the stratification of patients into distinct disease subgroups based on their autoantibody profiles, an approach which is designed to help predict treatment response and support better patient management.


Oncimmune has developed a pipeline of NavigAID stratification arrays, based on autoantibody signatures, for a number of autoimmune diseases. These have been created following our close collaboration and communication with a number of key industry opinion leaders, advocacy groups and major pharmaceutical and biotech companies, and address the following key questions

  • Can we ensure enrolment of an appropriate patient population?
  • Can we identify patients with high disease activity?
  • Can we predict disease-specific organ damage?
  • Can we stratify autoimmune diseases to allow enrichment/prediction of responders?

Oncimmune has developed its NavigAID arrays to address these questions, and has been engaged by many of top pharmaceutical companies to support their product development. For more information on how the NavigAID tools are being used for autoimmune diseases, please see below.